Abstract SY10-02: Pan-cancer Study of Recurrent and Heterogeneous RNA Aberrations and Association with Whole-Genome Variants
Samirkumar Amin,Philip Awadalla,Andrew Biankin,Paul Boutros,Alvis Brazma,Angela Norie Brooks,Claudia Calabrese,David Chang,Aurélien Chateigner,Ken Chen,Zechen Chong,Brian Craft,Chad Creighton,Deniz Demircioğlu,Nuno Fonseca,Milana Frenkel-Morgenstern,Gad Getz,Jonathan Göke,Mary Goldman,Liliana Greger,Syed Haider,Yao He,Katherine Hoadley,Yuan Ji,Andre Kahles,Ekta Khurana,Jan Korbel,Kjong Lehmann,Han Liang,Fenglin Liu,Maximillian Marin,Matthew Meyerson,Akinyemi Ojesina,Francis Ouellette,Chandra Pedamallu,Marc Perry,Gunnar Rätsch,Roland Schwarz,Yuichi Shiraishi,Cameron Soulette,Oliver Stegle,Patrick Tan,Alfonso Valencia,Linda Xiang,Christina Yung,Junjun Zhang,Fan Zhang,Zemin Zhang,Jingchun Zhu
DOI: https://doi.org/10.1158/1538-7445.am2017-sy10-02
IF: 11.2
2017-01-01
Cancer Research
Abstract:Abstract Whole-exome sequencing studies have transformed our understanding of recurrent somatic mutations that contribute to cancer pathogenesis; however, these studies limit our ability to identify cancer-associated mutations to those that cause protein-coding changes. To more comprehensively catalogue cancer-associated gene alterations, we have extensively characterized tumor transcriptomes from 1,220 donors with matched whole-genome sequence data to identify recurrent RNA-level aberrations. Specifically, we created a unified RNA-Seq analysis pipeline including sequence alignment and quality control and subsequently identified gene alterations through outlier detection from estimated gene expression levels, alternative splicing, alternative transcription starts, and allele-specific expression and through identified RNA-edited sites and gene fusions. Our data represent an extensive catalog of RNA aberrations for each gene across 27 cancer types. We have also tested for genetic associations with these RNA phenotypes. Using an integrative analysis approach, we have mapped genome-wide cis and trans effects on individual RNA phenotypes, considering both common germline variants as well as somatic SNVs in gene promoters, enhancers, and intronic and other regions. Many of the regulatory associations we identify are not accessible by exome sequencing, underlining the importance of whole-genome sequence data. Utilizing this RNA-centric view, we have identified genes that are recurrently altered, yet have not been previously characterized as cancer genes or identified through DNA-level driver gene analysis. To identify further supporting evidence that these recurrent alterations are potential drivers, we identified genes with mutually exclusive RNA-level alterations. Our findings reveal new insights into selective advantages of somatic changes and molecular mechanisms of cancer. This work is by the Transcriptome Working Group of the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium and authors are listed in alphabetical order. Citation Format: Samirkumar Amin, Philip Awadalla, Andrew Biankin, Paul Boutros, Alvis Brazma, Angela Norie Brooks, Claudia Calabrese, David Chang, Aurélien Chateigner, Ken Chen, Zechen Chong, Brian Craft, Chad Creighton, Deniz Demircioğlu, Nuno Fonseca, Milana Frenkel-Morgenstern, Gad Getz, Jonathan Göke, Mary Goldman, Liliana Greger, Syed Haider, Yao He, Katherine Hoadley, Yuan Ji, Andre Kahles, Ekta Khurana, Jan Korbel, Kjong Lehmann, Han Liang, Fenglin Liu, Maximillian Marin, Matthew Meyerson, Akinyemi Ojesina, Francis Ouellette, Chandra Pedamallu, Marc Perry, Gunnar Rätsch, Roland Schwarz, Yuichi Shiraishi, Cameron Soulette, Oliver Stegle, Patrick Tan, Alfonso Valencia, Linda Xiang, Christina Yung, Junjun Zhang, Fan Zhang, Zemin Zhang, Jingchun Zhu. Pan-cancer study of recurrent and heterogeneous RNA aberrations and association with whole-genome variants [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr SY10-02. doi:10.1158/1538-7445.AM2017-SY10-02